A single-center, randomized, open-label, single-dose, two-period, two-crossover study to evaluate the bioavailability of Jungliflozin capsules and Jungliflozin pyroglutamate capsules in healthy subjects under fasting conditions
Latest Information Update: 19 May 2025
At a glance
- Drugs Olorigliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
Most Recent Events
- 19 May 2025 New trial record